| Discrete Choice Experiments in Health Economics: Past, Present and Future |
66 |
| Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries |
37 |
| German Value Set for the EQ-5D-5L |
37 |
| Discounting in Economic Evaluations |
37 |
| Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System |
29 |
| A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D |
28 |
| Using Latent Class Analysis to Model Preference Heterogeneity in Health: A Systematic Review |
21 |
| Cost-Effectiveness Thresholds: the Past, the Present and the Future |
21 |
| The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence |
18 |
| Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets |
16 |
| Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations |
15 |
| Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L |
15 |
| Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30 |
12 |
| Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO) |
12 |
| The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review |
12 |
| Spillover Effects on Caregivers' and Family Members' Utility: A Systematic Review of the Literature |
11 |
| Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial |
11 |
| Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies |
11 |
| Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review |
10 |
| Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden |
10 |
| Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations |
10 |
| Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe |
10 |
| Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review |
10 |
| Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States |
10 |
| One Method, Many Methodological Choices: A Structured Review of Discrete-Choice Experiments for Health State Valuation |
10 |
| The Future of Precision Medicine: Potential Impacts for Health Technology Assessment |
10 |
| Head-to-Head Comparison of EQaEuro5DaEuro3L and EQaEuro5DaEuro5L Health Values |
9 |
| Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions |
9 |
| Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review |
9 |
| Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review |
9 |
| Transparency in Decision Modelling: What, Why, Who and How? |
8 |
| Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References? |
8 |
| Future Costs in Cost-Effectiveness Analyses: Past, Present, Future |
8 |
| Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues |
8 |
| Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models |
7 |
| Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges |
7 |
| A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis |
7 |
| EQ-5D-5L Valuation for the Malaysian Population |
7 |
| The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments |
7 |
| Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany |
7 |
| Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time |
6 |
| Mapping the Paediatric Quality of Life Inventory (PedsQL (TM)) Generic Core Scales onto the Child Health Utility Index-9 Dimension (CHU-9D) Score for Economic Evaluation in Children |
6 |
| A Practical Guide to Conducting a Systematic Review and Meta-analysis of Health State Utility Values |
6 |
| Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer |
6 |
| An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis |
6 |
| Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin |
6 |
| Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review |
6 |
| Autologous Chondrocyte Implantation with Chondrosphere for Treating Articular Cartilage Defects in the Knee: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
6 |
| Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review |
6 |
| Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy |
6 |
